The advancement of adoptive cell therapy has changed perspectives in solid organ transplantation. Immunosuppressive maintenance therapy in transplantation efficiently prevents allograft rejection, but is the main driver of cardio-metabolic complications, death caused by infections, malignancies, and cardiovascular disease.1,2 Minimization strategies for immunosuppression however are not unlimited and not without risk.3 Early phase 1/2a studies indicate that adoptive transfer of autologous Tregs in de novo living donor kidney allograft recipients is safe and enables reduction of triple-drug immunosuppression to low-dose tacrolimus monotherapy in the majority of patients.
Dirk Kuypers (2026) studied this question.